ATNM_OUT_1 [2025-03-25 09:52:34 -0400] 2671 Bytes | 677 tokens | Cum: 677 tkns (8.46% of 8k)
==========================================================================

Turbo, you got one job - predict the hottest stocks of the day -- before everyone else does! Ha! So today we're looking at Actinium Pharmaceuticals (ATNM) which is at 1.784065 up from 1.49. So, I pulled together a bunch of data for you to look over real fast. It's still early, 9:52:32 AM on Tue Mar 25, 2025 -0400. So, what's the verdict? You're the expert!

Here's the first list of news for Actinium Pharmaceuticals:

C1 - Today 06:00AM - Actinium Pharmaceuticals to Host KOL Investor Call at 8am ET Today to Highlight Revamped Clinical Programs and Expanded Market Opportunities Including Newly Initiated Actimab-A Solid Tumor Program
C2 - Mar-24-25 04:15PM - Actinium Pharmaceuticals Announces Supply Agreement with Eckert & Ziegler for Ac-225 Radioisotope to Support Comprehensive Development Activities
C3 - Mar-20-25 08:00AM - Actinium Pharmaceuticals Announces Research Collaboration with Memorial Sloan Kettering to Support Further Clinical Expansion of Actimab-A's Backbone Therapy Strategy
C4 - Mar-19-25 08:30AM - Actinium Pharmaceuticals to Host Investor KOL Call with Dr. Ehab Atallah of the Medical College of Wisconsin and Provide a Pipeline Update Highlighting Revamped Clinical Programs and Expanded Market Opportunities for Actimab-A and Iomab-ACT with Clinical Data in 2H:2025
C5 - Mar-19-25 08:30AM 08:11AM - Actinium Pharmaceuticals launches clinical trial for Actimab-A in combination
C6 - Mar-18-25 08:00AM - Actinium Pharmaceuticals Announces Clinical Trial Program in Solid Tumors Combining Actimab-A with PD-1 Checkpoint Inhibitors KEYTRUDA and OPDIVO
C7 - Mar-17-25 08:50AM - Actinium Pharmaceuticals Announces Publication of Actimab-A + CLAG-M Trial Results in Patients with Relapsed or Refractory Acute Myeloid Leukemia in the Peer-Reviewed Journal Leukemia
C8 - Mar-12-25 08:00AM - Actinium Pharmaceuticals to Participate at the 37th Annual Roth Conference

ONLY 3 RULES for AI:
==============
1) I am a document retrieval system. You are the analyst-investigator.
2) You can request items from my lists to get more info on Actinium Pharmaceuticals (ATNM)
3) AFTER requesting and reading News and SEC filings you'll write a summary, set a score, high price target and headline.
Now, your response should be only 2 or 3 chars. You can say ex., C1, C2, etc., or NEX
The NEX command delivers the NEXt list of News/SEC/Metrics
There are several more lists that use our unified document retrieval system in subsequent prompts.
Your predictons will be compared to reality to rate your accuracy. Try to predict accurately. GOOD LUCK!
Please request a document, read, summarize and score. Say something like "C1".

ATNM_OUT_3 [2025-03-25 09:52:43 -0400] 1056 Bytes | 260 tokens | Cum: 939 tkns (11.74% of 8k)
==========================================================================

Showing C1 (chunk 1 of 8): C1:
**Actinium Pharmaceuticals to Host KOL Investor Call at 8am ET Today to Highlight Revamped Clinical Programs and Expanded Market Opportunities Including Newly Initiated Actimab-A Solid Tumor Program**
Date: Today 06:00AM
Source: (PR Newswire)
URL: https://www.prnewswire.com/news-releases/actinium-pharmaceuticals-to-host-kol-investor-call-at-8am-et-today-to-highlight-revamped-clinical-programs-and-expanded-market-opportunities-including-newly-initiated-actimab-a-solid-tumor-program-302409947.html

-       Actinium will present 3 separate multi-billion-dollar market opportunities for Actimab-A and Iomab-ACT in myeloid malignancies, solid tumors and cell & gene therapy conditioning

-       Dr.Ehab Atallah, Professor of Medicine at theMedical College of Wisconsinto highlight Actimab-A clinical results, mutation agnostic mechanism and backbone therapy potential

-       Clinical proof of

-- More of this article? (say: MOR) or Next section? (say: NEX) (only 3 chars. - please don't summarize yet)

ATNM_OUT_5 [2025-03-25 09:52:44 -0400] 1045 Bytes | 249 tokens | Cum: 1302 tkns (16.28% of 8k)
==========================================================================

Showing C1 (chunk 2 of 8): concept data from frontline AML trial under NCI CRADA, Actimab-A solid tumor program with PD-1 checkpoint inhibitors and Iomab-ACT commercial CAR-T trial together with other expected 2025 milestones to be outlined

-       Actinium to highlight manufacturing infrastructure development activity to support revitalized clinical programs

NEW YORK,March 25, 2025/PRNewswire/ --Actinium Pharmaceuticals, Inc.(NYSE AMERICAN: ATNM) (Actinium or the Company), a pioneer in the development of targeted radiotherapies, will host an investor  call at8:00 am ETtoday that will feature KOL Dr.Ehab Atallah, Professor of Medicine at theMedical College of Wisconsinand principal investigator of the Actimab-A + CLAG-M combination trial in patients with relapsed/refractory acute myeloid leukemia (r/r AML). Dr. Atallah will discuss Actimab-A clinical results to date including recently published long-term surviv

-- More of this article? (say: MOR) or Next section? (say: NEX) (only 3 chars. - please don't summarize yet)

ATNM_OUT_7 [2025-03-25 09:52:46 -0400] 1012 Bytes | 277 tokens | Cum: 1581 tkns (19.76% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

A1 - 2025-03-24T20:47:13Z - Actinium Pharmaceuticals Announces Supply Agreement with Eckert & Ziegler for Ac-225 Radioisotope to...
A2 - 2025-03-24T20:24:57Z - Actinium secures Ac-225 supply for cancer therapy trials By Investing.com...
A3 - 2025-03-24T20:21:25Z - Actinium Pharma (ATNM) Announces Supply Agreement with Eckert & Ziegler for Ac-225 Radioisotope to S...
A4 - 2025-03-20T13:21:16Z - Actinium Pharmaceuticals Announces Research Collaboration with Memorial Sloan Kettering to Support F...
A5 - 2025-03-20T12:01:02Z - Actinium Pharmaceuticals Announces Research Collaboration with Memorial Sloan Kettering to Support F...

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

ATNM_OUT_9 [2025-03-25 09:52:47 -0400] 1038 Bytes | 295 tokens | Cum: 1878 tkns (23.47% of 8k)
==========================================================================

Showing A1 (chunk 1 of 2): A1:
**Actinium Pharmaceuticals Announces Supply Agreement with Eckert & Ziegler for Ac-225 Radioisotope to Support Comprehensive Development Activities**Date: 2025-03-24Source: {'uri': 'eagletribune.com', 'dataType': 'news', 'title': 'Eagle-Tribune'}URL: https://www.eagletribune.com/region/actinium-pharmaceuticals-announces-supply-agreement-with-eckert-ziegler-for-ac-225-radioisotope-to-support-comprehensive/article_7b70f8f9-c688-590b-8c87-4ca1c8ea4815.htmlNEW YORK, March 24, 2025 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a pioneer in the development of targeted radiotherapies, today announced it has entered into an agreement for the supply of Actinium-225 (Ac-225) with Eckert & Ziegler. Under this agreement, Actinium Pharmaceuticals will have access to Eckert & Ziegler's high-quality Actinium-225 to further develop its lead product A

-- More of this article? (say: MOR) or Next section? (say: NEX) (only 3 chars. - please don't summarize yet)

ATNM_OUT_11 [2025-03-25 09:52:56 -0400] 763 Bytes | 173 tokens | Cum: 2053 tkns (25.66% of 8k)
==========================================================================

Showing A1 (chunk 2 of 2): ctimab-A as well as additional early and late-stage development candidates for both U.S. and international clinical trials.

Targeted radiotherapies using Ac-225 have shown great promise in the treatment of cancer. The radioisotope releases powerful alpha particles with high energy and low penetration depth, enabling precise targeting of tumor cells, including hard-to-reach micrometastases, while minimizing effects on surrounding healthy tissue. Actimab-A is an Ac-225 based radiotherapy agent, directed against CD33, a receptor overexpressed in patients with acute myeloid leukemia (AML) and other myeloid indications.

-- More of this article? (say: MOR) or Next section? (say: NEX) (only 3 chars. - please don't summarize yet)

ATNM_OUT_13 [2025-03-25 09:52:57 -0400] 1088 Bytes | 339 tokens | Cum: 2539 tkns (31.74% of 8k)
==========================================================================

This is our final list of news.
News AI can literally read just by asking.
Don't miss the breaking news!

B1 - 2024-12-16T15:53:00Z - Targeted Alpha Therapy Market, Drugs Approval, Proprietary Technologies & Clinical Trials: 20+ Drugs of Targeted Alpha Therapy In Clinical Trials
B2 - 2024-10-21T17:00:00Z - Allogeneic Hematopoietic Stem Cell Transplant Market to Grow Rapidly During the Study Period (2020–2034) | DelveInsight
B3 - 2024-09-09T08:56:00Z - Lutetium-177 Industry Research Report 2024: Carrier Added Lutetium-177, Non-Carrier-Added Lutetium-177 - Global Forecast 2024-2030
B4 - 2024-06-20T13:40:12Z - Is Actinium Pharmaceuticals (ATNM) Outperforming Other Medical Stocks This Year?
B5 - 2024-06-04T13:40:10Z - Is Affimed (AFMD) Outperforming Other Medical Stocks This Year?
B6 - 2024-01-06T10:58:00Z - The Russell 2000 Index has soared, but you might be better off looking elsewhere for quality small-cap stocks

Request an article by its reference number. (Ex., "B1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

ATNM_OUT_15 [2025-03-25 09:53:02 -0400] 935 Bytes | 235 tokens | Cum: 2776 tkns (34.70% of 8k)
==========================================================================

Showing B1 (chunk 1 of 1): B1:
**Targeted Alpha Therapy Market, Drugs Approval, Proprietary Technologies & Clinical Trials: 20+ Drugs of Targeted Alpha Therapy In Clinical Trials**Date: Unknown DateSource: Unknown SourceURL: https://www.globenewswire.com/news-release/2024/12/16/2997669/28124/en/Targeted-Alpha-Therapy-Market-Drugs-Approval-Proprietary-Technologies-Clinical-Trials-20-Drugs-of-Targeted-Alpha-Therapy-In-Clinical-Trials.htmlThe article discusses the growing field of targeted alpha therapy, a novel approach in radiopharmaceuticals that utilizes alpha emitters to precisely target and eliminate diseased tissues. It highlights the approval of Xofigo, the first approved alpha-emitting radiopharmaceutical, and the surge of innovative preclinical and clinical candidates in development by various companies.

-- More of this article? (say: MOR) or Next section? (say: NEX) (only 3 chars. - please don't summarize yet)

ATNM_OUT_17 [2025-03-25 09:53:04 -0400] 1070 Bytes | 263 tokens | Cum: 3125 tkns (39.06% of 8k)
==========================================================================

This is our list of SEC filings.
If empty, the search returned no recent filings.

S1 - 2024-11-14 10-Q PART I - FIN INFO

ITEM 1. UNAUDITED FIN STATEMENTS

The accompanying condensed CONS financial statements have been prepared by Actinium Pharmaceuticals, Inc., or the Company, and are unaudited. In the opinion of management, all adjustments (which in...

S2 - 2024-11-14 10-Q PART I - FIN INFO

ITEM 1. UNAUDITED FIN STATEMENTS

The accompanying condensed CONS financial statements have been prepared by Actinium Pharmaceuticals, Inc., or the Company, and are unaudited. In the opinion of management, all adjustments (which in...

S3 - 2024-08-05 10-Q PART I - FIN INFO

ITEM 1. UNAUDITED FIN STATEMENTS

The accompanying condensed CONS financial statements have been prepared by Actinium Pharmaceuticals, Inc., or the Company, and are unaudited. In the opinion of management, all adjustments (which in...

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

ATNM_OUT_19 [2025-03-25 09:53:05 -0400] 1038 Bytes | 218 tokens | Cum: 3345 tkns (41.81% of 8k)
==========================================================================

Showing S1 (chunk 1 of 6): S1:
PART I - FINANCIAL INFORMATION

ITEM 1. UNAUDITED FINANCIAL STATEMENTS

The accompanying condensed consolidated financial statements have been prepared by Actinium Pharmaceuticals, Inc., or the Company, and are unaudited. In the opinion of management, all adjustments (which include only normal recurring adjustments) necessary to present fairly the financial position at September 30, 2024 and December 31, 2023, and the results of operations and cash flows for the three months and nine months ended September 30, 2024 and 2023, respectively, have been made. Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted. It is suggested that these financial statements be read in conjunction with the financial statements and notes th

-- More of this article? (say: MOR) or Next section? (say: NEX) (only 3 chars. - please don't summarize yet)

ATNM_OUT_21 [2025-03-25 09:53:07 -0400] 1038 Bytes | 273 tokens | Cum: 3620 tkns (45.25% of 8k)
==========================================================================

Showing S1 (chunk 2 of 6): ereto included in the Companys audited financial statements for the year ended December 31, 2023 in the Companys Annual Report on Form 10-K. The results of operations for the three months and nine months ended September 30, 2024 are not necessarily indicative of the operating results for the full year.

Actinium Pharmaceuticals, Inc.

Condensed Consolidated Balance Sheets

(Unaudited)

(amounts in thousands, except share and per share data)

September 30, 2024 December 31, 2023 (Unaudited) Assets Current Assets: Cash and cash equivalents $ 78,660 $ 76,677 Prepaid expenses and other current assets 860 1,586 Total Current Assets 79,520 78,263 Property and equipment, net of accumulated depreciation of $ 844 and $ 694 412 550 Restricted cash long term 322 313 Operating leases right-of-use assets 1,838 2,289 Finance leases right-of-use assets 22 30 Total Assets $ 82,114 $ 81,445 Liabiliti

-- More of this article? (say: MOR) or Next section? (say: NEX) (only 3 chars. - please don't summarize yet)

ATNM_OUT_23 [2025-03-25 09:53:12 -0400] 1038 Bytes | 288 tokens | Cum: 3910 tkns (48.88% of 8k)
==========================================================================

Showing S1 (chunk 3 of 6): es and Stockholders Equity Current Liabilities: Accounts payable and accrued expenses $ 7,195 $ 7,953 Operating leases current liability 549 530 Finance leases current liability 11 11 Total Current Liabilities 7,755 8,494 Long-term license revenue deferred 35,000 35,000 Long-term operating lease obligations 1,139 1,553 Long-term finance lease obligations 12 19 Total Liabilities 43,906 45,066 Commitments and contingencies

Stockholders Equity: Preferred stock, $ 0.001 par value; 50,000,000 shares authorized, 0 shares issued and outstanding -

-

Common stock, $ 0.001 par value; 1,000,000,000 shares authorized; 31,195,891 and 27,634,213 shares issued and outstanding, respectively 31 28 Additional paid-in capital 407,351 373,934 Accumulated deficit ( 369,174 ) ( 337,583 ) Total Stockholders Equity 38,208 36,379 Total Liabilities and Stockholders Equity $ 82,114 $ 81,445

See accompa

-- More of this article? (say: MOR) or Next section? (say: NEX) (only 3 chars. - please don't summarize yet)

ATNM_OUT_25 [2025-03-25 09:53:30 -0400] 4297 Bytes | 1206 tokens | Cum: 5216 tkns (65.20% of 8k)
==========================================================================

This is our set of metrics.
Please analyze the numbers.

+---------------------+----------------------+----------------------+-------------------------+------------------------+-----------------------+
| Volume: 226,535 | SMA50: 47.62% | Market Cap: 56.27M | Option/Short: Yes / Yes | Sales past 5Y: -27.50% | Sales Surprise: - |
+---------------------+----------------------+----------------------+-------------------------+------------------------+-----------------------+
| Avg Volume: 239.73K | SMA200: -33.76% | Shs Outstand: 31.20M | Short Float: 7.39% | Employees: 49 | EPS Surprise: -13.18% |
+---------------------+----------------------+----------------------+-------------------------+------------------------+-----------------------+
| Rel Volume: 14.09 | Perf Week: 51.57% | Shs Float: 30.40M | Short Ratio: 9.37 | Debt/Eq: 0.04 | P/E: - |
+---------------------+----------------------+----------------------+-------------------------+------------------------+-----------------------+
| RSI (14): 76.04 | Perf Month: 54.16% | Inst Own: 28.73% | Short Interest: 2.25M | Sales Y/Y TTM: 80.00% | Earnings: Mar 14 |
+---------------------+----------------------+----------------------+-------------------------+------------------------+-----------------------+
| ATR (14): 0.12 | Perf Quarter: 61.04% | Insider Own: 2.54% | Beta: -0.17 | ROE: -100.05% | |
+---------------------+----------------------+----------------------+-------------------------+------------------------+-----------------------+
| SMA20: 45.73% | Index: RUT | Insider Trans: 0.00% | Sales Q/Q: - | ROI: -103.95% | |
+---------------------+----------------------+----------------------+-------------------------+------------------------+-----------------------+

The next section covers any insider trading.
If this section may be blank due to no recent filings.

[Company Financial Summary]
[Company Details]
Name: Actinium Pharmaceuticals, Inc
Market Cap: 46481877.589999996
Shares Outstanding: 31195891
Sector: PHARMACEUTICAL PREPARATIONS

[Financial Statements - Latest Quarter]
Total Assets: N/A
Total Liabilities: N/A
Total Equity: N/A
Revenue (Quarter): {'value': 81000, 'unit': 'USD', 'label': 'Revenues', 'order': 100}
Net Income: {'value': -40915000.0, 'unit': 'USD', 'label': 'Net Income/Loss', 'order': 3200}
Earnings Per Share (EPS): N/A

[Price Metrics - Last 30 Days]
Latest Close: 1.83
Average Volume: 274674.45
30-Day High: 1.83
30-Day Low: 1.06

[Detailed Financials: Q3 2024]
- Total Assets: $82,114,000.0
- Total Liabilities: $43,906,000.0
- Total Equity: $38,208,000.0
- Current Assets: $79,520,000.0
- Current Liabilities: $7,755,000.0

[Income Statement: Q3 2024]
- Revenue: $0.00
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): -0.37

[Cash Flow Statement: Q3 2024]
- Net Cash Flow: $-7,373,000.0

[Detailed Financials: Q2 2024]
- Total Assets: $89,861,000.0
- Total Liabilities: $46,026,000.0
- Total Equity: $43,835,000.0
- Current Assets: $87,068,000.0
- Current Liabilities: $9,728,000.0

[Income Statement: Q2 2024]
- Revenue: $0.00
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): -0.38

[Cash Flow Statement: Q2 2024]
- Net Cash Flow: $1,982,000.0
==== END OF FINANCIAL REPORT ====

You are now requested to make a summary analysis.
Save explaining why you didn't have enough information for the final survey.

Now, complete this report with the following:

1) Brief Summary: explain your findings in succinct wording.
2) MARKET_SCORE: If you calculate a 92% likelihood of an upward moves, say: MARKET_SCORE[92]
3) PRICE_TARGET: If you think the high today will be 50% higher, add to the price.
Eg., If the current price is $5.00, add 50%. Thus, PRICE_TARGET[$7.50] -- It should be at or above the current price.
4) Provide a thought-provoking take, 6-10 words, to use for the headline of this news story.
Like this: AI_RPT_HEADLINE: [6-12 words headline for news story, distilled from summary]

1) Brief Summary, 2) MARKET_SCORE, 3) PRICE_TARGET, and 4) AI_RPT_HEADLINE

ATNM_OUT_27 [2025-03-25 09:53:33 -0400] 676 Bytes | 167 tokens | Cum: 5635 tkns (70.44% of 8k)
==========================================================================

Finally, if more data could have improved your confidence which would you have chosen? **Choose one option:**
-> X0 <- Nothing more would have helped my analysis
-> X1 <- More stock-specific news
-> X2 <- More SEC filings (10-K, 10-Q, 8-K) Financials, risk disclosures, and business changes
-> X3 <- More SEC Insider Trading (Form 3, 4, 5) Direct buys/sells from executives and institutions
-> X4 <- Broader sector & market news
-> X5 <- Your past analysis on similar companies (specify metrics)
-> X6 <- More financial metrics
-> X7 <- Your past analysis on this exact company
-> X8 <- Something altogether different (explain...)

ATNM_IN_29 [2025-03-25 09:53:35 -0400] 126 Bytes | 29 tokens | Cum: 5692 tkns (71.15% of 8k)
==========================================================================

====================================
[2025-03-25 06:53:35] # Analysis Completed
Elapsed Time: 62.96 seconds